Ascendis Pharma (ASND) Tops Q1 EPS by 68c

Ascendis Pharma (NASDAQ: ASND) reported Q1 EPS of (EUR1.98), EUR0.68 better than the analyst estimate of (EUR2.66). Revenue for the quarter came in at EUR28.97 million versus the consensus estimate of EUR21.15 million.

For earnings history and earnings-related data on Ascendis Pharma (ASND) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• Dollarama Inc. (DOL:CN) (DLMAF) PT Raised to Cdn$221 at BMO Capital
• Lennar Corp. (LEN) Misses Q2 EPS by 1c